Stapled versions of truncated orexin peptides still activated orexin receptors but with reduced potency, showing the approach is feasible but needs optimization.
4 stapling sites testedOnly central and N-terminal positions retained activity — C-terminal stapling eliminated receptor activation entirely
What the researchers found
Researchers used peptide stapling — a chemical technique that locks a peptide into a helical shape — on shortened versions of orexin-A to try to maintain their biological activity. The stapled peptides did activate orexin receptors, proving that the receptors can accommodate and respond to rigidly helical peptides. However, all stapled variants had reduced potency compared to the unmodified truncated peptide.
Stapling near the C-terminus (the business end of the peptide) completely killed activity. Central and N-terminal stapling positions kept the peptides active but weaker, likely because the rigid helix locked the peptide into a shape that wasn't quite optimal for receptor binding.
Why it matters
Orexin peptides regulate wakefulness and appetite, making them potential drug targets for narcolepsy and metabolic disorders. But natural orexin peptides are too large and unstable for practical drug use. Peptide stapling is a promising strategy to create smaller, more stable versions. This study shows the approach is feasible — stapled orexin peptides can still activate the receptor — but highlights the challenge of maintaining potency when you constrain a peptide's shape.
The numbers in context
19-amino-acid C-terminal fragment used · 4 stapling sites tested · orexin-A15-33 as starting peptide · α-aminoisobutyric acid substitutions also tested
How the study worked
The researchers took orexin-A15-33 (a 19-amino-acid fragment that retains full activity) and introduced hydrocarbon staples at four different positions along the peptide. They also tested replacing the staple with α-aminoisobutyric acid (Aib) residues at a suspected hinge region. All variants were tested for their ability to activate orexin receptors in cell-based assays measuring intracellular signaling.
Who was studied
In vitro cell-based receptor activation assays
What this study cannot tell us
This is an in-vitro study measuring receptor activation in cells, not in living animals. The stapled peptides all showed reduced potency, so the practical utility of this specific approach remains unclear. Stability improvements from stapling (resistance to degradation) were not directly measured in this study.
How to read the evidence
This is a preliminary in-vitro study exploring a peptide design strategy. It provides proof-of-concept data but is far from clinical application.
When this study was published
Published in 2018, this study established foundational structure-activity relationships for stapled orexin peptides that continue to inform peptide drug design efforts.
The bigger picture
Peptide stapling is one of the hottest techniques in peptide drug design, used to create more drug-like peptides that resist degradation and can potentially be taken orally. This study applies the technique to orexin peptides for the first time, establishing a structure-activity map that future researchers can build on. The finding that orexin receptors accept helical peptides opens the door to further optimization, even though these first-generation stapled versions aren't potent enough for clinical use.
Questions still open
- Can optimized stapling positions or different cross-linker chemistries restore full potency to stapled orexin peptides?
- Do the stapled orexin peptides show improved resistance to enzymatic degradation compared to unstapled versions?
- Could stapled orexin agonists eventually be developed as treatments for narcolepsy or other wakefulness disorders?
Common questions
What is peptide stapling and why is it useful?
Why are orexin peptides important for drug development?
Read the original research
Stapled truncated orexin peptides as orexin receptor agonists.
Peptides, 102, 54-60
Citation
Karhu, Lasse; Weisell, Janne; Turunen, Pauli M; Leino, Teppo O; Pätsi, Henri; Xhaard, Henri; Kukkonen, Jyrki P; Wallén, Erik A A. (2018). Stapled truncated orexin peptides as orexin receptor agonists.. Peptides, 102, 54-60. https://doi.org/10.1016/j.peptides.2018.02.004